Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality
Riemsma R, Al M, Blommestein H, Deshpande S, Ryder S, Worthy G, et al.
Record ID 32013000884
English
Details
Project Status:
Completed
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/110701/#/
Year Published:
2013
URL for published report:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/110701/#/
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Myelodysplastic Syndromes
- Thalidomide
- Lenalidomide
- Immunologic Factors
- Angiogenesis Inhibitors
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.